-
公开(公告)号：US20240366816A1
公开(公告)日：2024-11-07
申请号：US18771562
申请日：2024-07-12
Applicant: University of Iowa Research Foundation
Inventor： Dongyoul Lee , Michael K. Schultz , Mengshi Li , Nicholas Baumhover , F. Christopher Pigge
Abstract: The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X wherein T is a SSTR2 targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.
-
公开(公告)号：US11179484B2
公开(公告)日：2021-11-23
申请号：US16312846
申请日：2017-06-26
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Frances L. Johnson , Somya Kapoor , Dongyoul Lee , Mengshi Li , Molly Martin
IPC: A61K51/04 , A61K47/64 , A61P35/00 , A61K38/08 , A61K47/54 , A61K47/60 , A61K31/167 , A61K31/192 , A61K31/437 , A61K31/4427 , A61K31/519
Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).
-
公开(公告)号：US12128115B2
公开(公告)日：2024-10-29
申请号：US17051037
申请日：2019-04-25
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Christopher Pigge , Mengshi Li , Moustafa Gabr , Edwin Sagastume
CPC classification number: A61K51/0482 , A61K45/06 , A61K51/0497 , A61K51/083
Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(═O)NHRa; each of R5-R12 is independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.
-
公开(公告)号：US20210228749A1
公开(公告)日：2021-07-29
申请号：US17051037
申请日：2019-04-25
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Christopher Pigge , Mengshi Li , Moustafa Gabr , Edwin Sagastume
Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(═O)NHRa; each of R5-R12 is independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.
-
公开(公告)号：US20250057914A1
公开(公告)日：2025-02-20
申请号：US18899589
申请日：2024-09-27
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Frances L. Johnson , Somya Kapoor , Dongyoul Lee , Mengshi Li , Molly Martin
Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.
The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I. T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits, and uses of the conjugate of Formula I.-
Patent Agency Ranking
公开(公告)号：US20250009912A1
公开(公告)日：2025-01-09
申请号：US18896069
申请日：2024-09-25
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Christopher Pigge , Mengshi Li , Moustafa Gabr , Edwin Sagastume
Abstract: A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R1-R4 is independently selected from the group consisting of CH2COORa and CH2C(═O)NHRa; each of R5-R12 is independently selected from the group consisting of II and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.
-
公开(公告)号：US20240398891A1
公开(公告)日：2024-12-05
申请号：US18750667
申请日：2024-06-21
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Frances L. Johnson , Somya Kapoor , Dongyoul Lee , Mengshi Li , Molly Martin
Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.
The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits, and uses of the conjugate of Formula I.-
公开(公告)号：US11576987B2
公开(公告)日：2023-02-14
申请号：US17507400
申请日：2021-10-21
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Frances L. Johnson , Somya Kapoor , Dongyoul Lee , Mengshi Li , Molly Martin
IPC: A61K51/04 , A61K47/54 , A61K47/64 , A61K47/60 , A61P35/00 , A61K31/167 , A61K31/192 , A61K31/437 , A61K31/4427 , A61K31/519 , A61K38/08
Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.
The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.-
公开(公告)号：US20220111080A1
公开(公告)日：2022-04-14
申请号：US17507400
申请日：2021-10-21
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Frances L. Johnson , Somya Kapoor , Dongyoul Lee , Mengshi Li , Molly Martin
IPC: A61K51/04 , A61K47/54 , A61K47/64 , A61K47/60 , A61P35/00 , A61K31/167 , A61K31/192 , A61K31/437 , A61K31/4427 , A61K31/519 , A61K38/08
Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.
The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.-
公开(公告)号：US20220072092A1
公开(公告)日：2022-03-10
申请号：US17531485
申请日：2021-11-19
Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventor： Michael K. Schultz , Frances L. Johnson , Somya Kapoor , Dongyoul Lee , Mengshi Li , Molly Martin
Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof.
The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I. T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits, and uses of the conjugate of Formula I.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
